Teleflex Incorporated announces that its anesthesia and respiratory business unit received 510(k) clearance for the ISO-Gard® Mask with ClearAir Technology, the companys novel product that helps to reduce clinician exposure to hazardous waste anesthetic gases.
The ISO-Gard Mask is designed to reduce waste anesthetic gas (WAG) within a nurses breathing zone to minimize the cumulative effect of low-level exposure to these hazardous gases in the post-anesthesia care unit (PACU). The multi-purpose mask scavenges WAG while simultaneously delivering oxygen to the patient. The patent-pending ClearAir technology provides unidirectional flow of oxygen through the mask to assure maximum FiO2.
Teleflex estimates that anesthetic gases are used in 20 million surgeries in the US annually and up to 100 million globally. When patients are recovering in the PACU, they exhale these gases which are then released into the nurses breathing zone and work environment. The Occupational Safety and Health Administration (OSHA) warns of several potential health effects from WAG exposure, including nausea, dizziness, headaches, and fatigue.
The PACU is currently a non-scavenged environment so other less-effective methods of waste gas removal are often relied upon, making it more difficult to control clinician exposure.
 I was surprised at the level of nitrous oxide and sevoflurane in the PACU from patient off-gassing from a recent study we conducted in a hospital in the Midwest, says James D. McGlothlin, MPH, PhD, CPE. Based on what I personally experienced during this study, I believe that waste anesthetic gases should be controlled in the PACU by a combination of engineering controls (i.e., scavenging systems), including regular maintenance of such equipment, and best practices by those who care for patients in the PACU.
The ISO-Gard Mask with ClearAir Technology is a featured addition to the Teleflex line of Hudson RCI® respiratory products.
Source: Teleflex Incorporated
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.